Trials
1 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Biliary Tract Cancer (BTC)
- Main trialPhase 3
- “The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS). Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Treatment will be continued until disease progression, death, withdraw consent, or completing 12 treatment cycles , whichever occurs first.”In the company’s words, NCT06622057 on ClinicalTrials.gov
- Other names
- Treatment group
Other drugs for Biliary Tract Cancer (BTC)
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- CTX-009Compass Therapeutics · Phase 2/3
- RilvegostomigAstraZeneca · Phase 3
- NanvuranlatJ-Pharma Co., Ltd. · Phase 3
- DurvalumabAstraZeneca · Phase 3
Coming up1
- 31 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2028 | D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer | |
| Phase 2/3Terminated | 31 Jul 2025 | Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | |
| Phase 1/2Completed | 28 Dec 2020 | Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026